Chinese investor to provide 300 million rubles for drug manufacturing at Medsintez

| By | Drug Manufacturing, Investments

Sverdlovsk region intends to expand a joint Russian-Chinese medical production facility in the city of Novouralsk by launching the manufacturing of antiviral drugs. This was announced in Harbin (China) by Alexey Orlov, the First Deputy Governor of the region.

“We already have an example of collaboration. The blood collection equipment is manufactured together with Chinese counterparts in Novouralsk. There are also plans to expand the range of manufactured products. This will include a line of antiviral drugs,” said Mr. Orlov.

He added that a Chinese investor may join the project, the cost of which is estimated at about 300 million rubles. These investments are required in order to launch the serial production of medicines that passed all necessary trials and were certified.

Mr. Orlov also added that the enterprise is planned to be located in a pharmaceutical cluster based on the Medsintez plant in Novouralsk. Today, the cluster includes about 30 enterprises. The timeframe for implementing the project will be announced after the investor makes a decision on its plans.

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.